Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 24

Publication Record

Connections

Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Ness RB, Edwards RP, Jensen A, Kjær SK, Høgdall E, Berchuck A, Cramer DW, Terry KL, Poole EM, Bandera EV, Paddock LE, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Webb PM
(2017) Br J Cancer 116: 1223-1228
MeSH Terms: Acetaminophen, Adult, Aged, Analgesics, Anti-Inflammatory Agents, Non-Steroidal, Anticarcinogenic Agents, Aspirin, Disease-Free Survival, Female, Humans, Middle Aged, Ovarian Neoplasms, Proportional Hazards Models, Risk Factors
Show Abstract · Added April 18, 2017
BACKGROUND - Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.
METHODS - Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).
RESULTS - Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).
CONCLUSIONS - Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.
0 Communities
1 Members
0 Resources
14 MeSH Terms
Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions.
Choi E, Hendley AM, Bailey JM, Leach SD, Goldenring JR
(2016) Gastroenterology 150: 918-30.e13
MeSH Terms: Animals, Anticarcinogenic Agents, Benzimidazoles, Cell Differentiation, Cell Lineage, Cell Proliferation, Cell Transformation, Neoplastic, Chief Cells, Gastric, Disease Progression, Female, Gene Expression Regulation, Neoplastic, Genes, ras, Genetic Predisposition to Disease, Humans, Macrophages, Male, Metaplasia, Mice, Inbred C57BL, Mice, Transgenic, Mitogen-Activated Protein Kinase Kinases, Mutation, Phenotype, Protein Kinase Inhibitors, Signal Transduction, Stomach Neoplasms, Time Factors, Transcriptional Activation
Show Abstract · Added March 28, 2016
BACKGROUND & AIMS - Gastric cancer develops in the context of parietal cell loss, spasmolytic polypeptide-expressing metaplasia (SPEM), and intestinal metaplasia (IM). We investigated whether expression of the activated form of Ras in gastric chief cells of mice leads to the development of SPEM, as well as progression of metaplasia.
METHODS - We studied Mist1-CreERT2Tg/+;LSL-K-Ras(G12D)Tg/+ (Mist1-Kras) mice, which express the active form of Kras in chief cells on tamoxifen exposure. We studied Mist1-CreERT2Tg/+;LSL-KRas (G12D)Tg/+;R26RmTmG/+ (Mist1-Kras-mTmG) mice to examine whether chief cells that express active Kras give rise to SPEM and IM. Some mice received intraperitoneal injections of the Mitogen-activated protein kinase kinase (MEK) inhibitor, selumetinib, for 14 consecutive days. Gastric tissues were collected and analyzed by immunohistochemistry, immunofluorescence, and quantitative polymerase chain reaction.
RESULTS - Mist1-Kras mice developed metaplastic glands, which completely replaced normal fundic lineages and progressed to IM within 3-4 months after tamoxifen injection. The metaplastic glands expressed markers of SPEM and IM, and were infiltrated by macrophages. Lineage tracing studies confirmed that the metaplasia developed directly from Kras (G12D)-induced chief cells. Selumetinib induced persistent regression of SPEM and IM, and re-established normal mucosal cells, which were derived from normal gastric progenitor cells.
CONCLUSIONS - Expression of activated Ras in chief cells of Mist1-Kras mice led to the full range of metaplastic lineage transitions, including SPEM and IM. Inhibition of Ras signaling by inhibition of MEK might reverse preneoplastic metaplasia in the stomach.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.
0 Communities
2 Members
0 Resources
27 MeSH Terms
Green tea gets molecular.
Rouzer CA, Marnett LJ
(2011) Cancer Prev Res (Phila) 4: 1343-5
MeSH Terms: Animals, Anticarcinogenic Agents, Catechin, Fibroblasts, Humans, JNK Mitogen-Activated Protein Kinases, Mice, Mice, Knockout, Models, Chemical, NF-kappa B, NIMA-Interacting Peptidylprolyl Isomerase, Neoplasms, Peptidylprolyl Isomerase, Tea, Transcription Factor AP-1, Transcription, Genetic
Show Abstract · Added March 7, 2014
Green tea and its major polyphenolic flavonoid, epigallocatechin gallate (EGCG), have been credited with cancer chemopreventive activity for many years; the mechanism for this activity, however, has remained obscure. Now, as reported in this issue of the journal (beginning on page 1366), Urusova and colleagues showed direct binding of EGCG to the peptidyl prolyl cis/trans isomerase Pin1, which inhibited Pin1 enzymatic activity. They showed that Pin1 expression is required for EGCG effects on cell growth, c-Jun activation, and transcription regulation mediated by NF-κB and activator protein-1. The data provide a glimpse of the mechanism of action of EGCG and set a new bar for the future study of natural products with chemopreventive activity.
©2011 AACR.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention.
Oates JA
(2011) Cancer Prev Res (Phila) 4: 1145-8
MeSH Terms: Adenoma, Anticarcinogenic Agents, C-Reactive Protein, Celecoxib, Colorectal Neoplasms, Female, Humans, Male, Pyrazoles, Sulfonamides
Show Abstract · Added March 20, 2014
COX-2 inhibition reduces the incidence of colorectal neoplasia. The increased risk of thrombotic cardiovascular events produced by selective or nonselective COX-2 inhibitors, however, has confounded the consideration of employing them in cancer prevention. Developing a strategy for preventing colorectal cancer by inhibiting COX-2 depends on research advances in several key areas, including predictive biomarkers to identify people at the lowest risk for cardiovascular events, the molecular mechanisms whereby interdicting the COX-2 pathway produces thrombotic events, and the pharmacology of the widely divergent agents that act on COX-2 and its downstream pathway.
1 Communities
1 Members
0 Resources
10 MeSH Terms
Evolving concepts in lung carcinogenesis.
Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett SM
(2011) Semin Respir Crit Care Med 32: 32-43
MeSH Terms: Animals, Anticarcinogenic Agents, Epigenesis, Genetic, Epigenomics, Gene Expression Profiling, Genomics, High-Throughput Nucleotide Sequencing, Humans, Inflammation, Lung Neoplasms, Mutation, Neoplastic Stem Cells, Proteomics
Show Abstract · Added February 16, 2016
Lung carcinogenesis is a complex, stepwise process that involves the acquisition of genetic mutations and epigenetic changes that alter cellular processes, such as proliferation, differentiation, invasion, and metastasis. Here, we review some of the latest concepts in the pathogenesis of lung cancer and highlight the roles of inflammation, the "field of cancerization," and lung cancer stem cells in the initiation of the disease. Furthermore, we review how high throughput genomics, transcriptomics, epigenomics, and proteomics are advancing the study of lung carcinogenesis. Finally, we reflect on the potential of current in vitro and in vivo models of lung carcinogenesis to advance the field and on the areas of investigation where major breakthroughs will lead to the identification of novel chemoprevention strategies and therapies for lung cancer.
© Thieme Medical Publishers.
0 Communities
1 Members
0 Resources
13 MeSH Terms
Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway.
Nagaraj NS, Anilakumar KR, Singh OV
(2010) J Nutr Biochem 21: 405-12
MeSH Terms: Allyl Compounds, Anticarcinogenic Agents, Antineoplastic Agents, Phytogenic, Apoptosis, Apoptotic Protease-Activating Factor 1, Caspase 3, Caspase 9, Caspase Inhibitors, Cell Line, Tumor, Chemoprevention, Cystatin B, Cytochromes c, Disulfides, Fas-Associated Death Domain Protein, Garlic, Gene Expression Regulation, Neoplastic, Humans, Mitochondria, Neoplasms, Plant Roots, Protein Transport, Signal Transduction, bcl-2-Associated X Protein
Show Abstract · Added June 14, 2013
Diallyl disulfide (DADS), an important component of garlic (Allium sativum) derivative, has been demonstrated to exert a potential molecular target against human cancers. We investigated DADS-induced expressions of Apaf1, cystatin B, caspase-3 and FADD (fas-associated protein with death domain) in breast, prostate and lung cancer cells. These showed coincident data when further examined by quantitative reverse transcription-polymerase chain reaction and Western blot analysis. Furthermore, DADS induced a marked amount of Bax translocation, cytochrome c release and activation of caspase-3 and caspase-9. DADS-treated tumor cells triggered mitochondria-mediated signaling pathways that led to a significant increase in apoptosis induction. Further studies with caspase-3 and caspase-9 inhibitors (zDEVD-fmk and zLEHD-fmk, respectively) proved that DADS induces apoptosis through a caspase-3-dependent pathway. DADS is only an agent used in the study. The molecular mechanism presented therefore provides strong additional support to the hypothesis that DADS is a strong inducer of apoptosis through a Bax-triggered mitochondria-mediated and caspase-3-dependent pathway. This study shows clearly that DADS causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. Therefore, the mitochondrial pathway might be the target for cancer chemoprevention and/or chemotherapy by DADS.
Published by Elsevier Inc.
0 Communities
1 Members
0 Resources
23 MeSH Terms
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
Sepmeyer JA, Greer JP, Koyama T, Zic JA
(2007) J Am Acad Dermatol 56: 584-7
MeSH Terms: Aged, Anticarcinogenic Agents, Bexarotene, Biopsy, Needle, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Immunohistochemistry, Lymphoma, T-Cell, Cutaneous, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Pilot Projects, Risk Assessment, Rosiglitazone, Single-Blind Method, Survival Analysis, Tetrahydronaphthalenes, Thiazolidinediones, Treatment Outcome
Show Abstract · Added March 20, 2014
Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.
0 Communities
1 Members
0 Resources
24 MeSH Terms
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM
(2006) Urology 67: 1257-61
MeSH Terms: Adenocarcinoma, Aged, Aged, 80 and over, Anticarcinogenic Agents, Carotenoids, Humans, Lycopene, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms
Show Abstract · Added May 27, 2014
OBJECTIVES - To report a prospective trial of lycopene supplementation in biochemically relapsed prostate cancer.
METHODS - A total of 36 men with biochemically relapsed prostate cancer were enrolled in a dose-escalating, Phase I-II trial of lycopene supplementation. Six consecutive cohorts of 6 patients each received daily supplementation with 15, 30, 45, 60, 90, and 120 mg/day for 1 year. The serum levels of prostate-specific antigen (PSA) and plasma levels of lycopene were measured at baseline and every 3 months. The primary endpoints were PSA response (defined as a 50% decrease in serum PSA from baseline), pharmacokinetics, and the toxicity/tolerability of this regimen.
RESULTS - A total of 36 patients were enrolled. The median age was 74 years (range 56 to 83), with a median serum PSA at entry of 4.4 ng/mL (range 0.8 to 24.9). No serum PSA responses were observed, and 37% of patients had PSA progression. The median time to progression was not reached. Toxicity was mild, with 1 patient discontinuing therapy because of diarrhea. Significant elevations of plasma lycopene were noted at 3 months and then appeared to plateau for all six dose levels. The plasma levels for doses between 15 and 90 mg/day were similar, with additional elevation only at 120 mg/day.
CONCLUSIONS - Lycopene supplementation in men with biochemically relapsed prostate cancer is safe and well tolerated. The plasma levels of lycopene were similar for a wide dose range (15 to 90 mg/day) and plateaued by 3 months. Lycopene supplementation at the doses used in this study did not result in any discernible response in serum PSA.
0 Communities
1 Members
0 Resources
13 MeSH Terms
Targeting cytokine receptors and pathways in the treatment of breast cancer.
Mayer IA
(2005) Cancer Treat Res 126: 243-62
MeSH Terms: Animals, Anticarcinogenic Agents, Breast Neoplasms, Humans, Receptors, Cytokine
Added March 5, 2014
0 Communities
1 Members
0 Resources
5 MeSH Terms
Novel strategies for the early detection and prevention of lung cancer.
Wardwell NR, Massion PP
(2005) Semin Oncol 32: 259-68
MeSH Terms: Anticarcinogenic Agents, Biomarkers, Tumor, Bronchoscopy, Gene Expression Profiling, Genomic Instability, Humans, Lung Neoplasms, Positron-Emission Tomography, Proteomics, Tomography, Spiral Computed
Show Abstract · Added March 5, 2014
Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced stage, when prognosis is poor. This article reviews new strategies being studied for the early detection of lung cancer. These strategies involve new methods of imaging (including low-dose computed tomography [CT] scanning), DNA analysis, and proteomic-based techniques. These strategies have not only improved our understanding of lung cancer but show promise in offering better survival to patients with this deadly disease. Of paramount importance in the search for methods of early detection is the need for the identification of the ideal population to screen, a multidisciplinary approach, and validation of promising techniques.
0 Communities
1 Members
0 Resources
10 MeSH Terms